A phase 2 study of Johnson & Johnson’s Inlexzo (gemcitabine intravesical system) found strong survival results after one year in patients with Bacillus Calmette-Guérin (“BCG”)-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer.
Data from a cohort of the SunRISe-1 study found that at a median follow-up of 15.9 months, the one-year disease-free survival rate was 74.3%. At one year, progression-free survival was 95.6%, and overall survival was 98%.
Also, 92.3% of participants did not require radical cystectomy.
